-
Exploring LRRK2 Substrate(s) for Parkinson Disease by Protein Arrays
… proteome chip with 4200 human proteins purified from a yeast expression system. We will then confirm the … We anticipate that we will indentify LRRK2 substrate(s) from protein arrays and post confirmation experiments. If we …
-
Development and Initial Characterization of an Enzyme-linked Immunosorbent Assay for the Candidate PD Risk Marker ST13
… heat shock protein 70, a molecule known to protect neurons from the toxic effects of alpha-synuclein in animal models … therapeutic may prevent debilitating symptoms of PD from ever appearing. Final Outcome It proved difficult to …
-
Specific Intracellular Targeting of Oligomeric Alpha-synuclein as a Potential Therapeutic for Parkinson's Disease
… they can block toxicity of the oligomers and clear them from the cell. A major advantage of targeting only the toxic … of alpha-synuclein provided partial or full protection from toxicity due to intracellular overexpression of …
-
Parkinson's Screening Questionnaire
… your speech slurred or softer? Do you have trouble rising from a chair? Do your lips, hands, arms and/or legs shake? … start a conversation. Print this page Used with permission from the following publication: York MK, Benge JF, Hunter C, …
-
Pre-clinical Development of a Vaccine Against Alpha-synuclein Based on Virus-like Particles
… antibodies in animals as well as humans. This is different from most other platforms where strong adjuvants not … resulting in failure to translate these observations from models to clinical efficacy in humans. We expect that …
-
Todd Sherer, Chief Executive Officer of The Michael J. Fox Foundation, Named To Advisory Council of Newly Formed National Center for Advancing Translational Sciences (NCATS)
September 14, 2012
… human diseases. “Streamlining the drug discovery process from the lab to the pharmacy shelf has been a key focus of … gain insight into other diseases while applying learnings from our experience in Parkinson’s — all to help propel the …